Showing 3201-3210 of 5621 results for "".
- LumiThera to Expand Research into Diabetic Retinopathy for Valeda Light Delivery Systemhttps://modernod.com/news/lumithera-to-expand-research-into-diabetic-retinopathy-for-valeda-light-delivery-system/2477299/LumiThera announced it has initiated further studies with the University of Wisconsin-Milwaukee to establish the use of their Photobiomodulation platform in diabetic retinopathy (DR). “Recent research in our labs in both preclinical and clinical areas hav
- Not All With AMD May Need Continuing Treatmenthttps://modernod.com/news/not-all-with-amd-may-need-continuing-treatment/2477294/A small number of patients with neovascular age-related macular degeneration (AMD) continue to maintain good vision years after cessation of anti-VEGF therapy, according to an analysis of trial results, as reported by Reuters. Howe
- Santen and Verily Establish Joint Venture to Develop and Commercialize Unique Ophthalmic Deviceshttps://modernod.com/news/santen-and-verily-establish-joint-venture-to-develop-and-commercialize-unique-ophthalmic-devices/2477285/Santen Pharmaceutical and Alphabet subsidiary Verily announced the establishment of a joint venture focused on applying microelectronics and scalable digital technologies to ophthalmology. The new joint venture is driven by a mission to improve eye health for people everywhere, starting by
- Optimal Atropine Concentration for Two Year Myopia Control Affirmedhttps://modernod.com/news/optimal-atropine-concentration-for-two-year-myopia-control-affirmed/2477255/Atropine 0.05% remains the optimal concentration for slowing myopia progression among Chinese children, the LAMP study extension shows, according to a Reuters report. In a 2011 study, atropine 0.01% – but not 0.1% or 0.5% 
- Mojo Vision Developing Smart Contact Lenshttps://modernod.com/news/mojo-vision-developing-smart-contact-lens/2477237/Mojo Vision announced it is building what it calls the “world’s first true smart contact lens,” called the Mojo Lens. Mojo Lens is a contact lens with a built-in display that gives people useful and timely information without forcing them to look down at a screen or losing focus on th
- The American Optometric Association (AOA) Launches Nationwide Campaign to Make 2020 the Year of the Eye Examhttps://modernod.com/news/the-american-optometric-association-aoa-launches-nationwide-campaign-to-make-2020-the-year-of-the-eye-exam/2477227/The American Optometric Association (AOA) announced the official launch of the #2020EyeExam campaign to make eye health and vision care a national priority in 2020. The public awareness campaign underscores the importance of receiving an in-person comprehensive eye examination with an AOA doctor
- The American Optometric Association Urges Employers to Pledge to Make 2020 the Year of the Eye Examhttps://modernod.com/news/the-american-optometric-association-urges-employers-to-pledge-to-make-2020-the-year-of-the-eye-exam/2477180/As part of the American Optometric Association’s (AOA) #2020EyeExam initiative, the organization and doctors of optometry nationwide are calling upon visionary companies across the country to join the 2020 Employer Pledge program–affirming the importance of caring for the overall health and
- Genentech/Roche’s Faricimab Phase 3 Program Fully Recruited with Enrollment Completion of Wet AMD Clinical Trialshttps://modernod.com/news/genentech-roches-faricimab-phase-3-program-fully-recruited-with-enrollment-completion-of-wet-amd-clinical-trials/2477161/Genentech and Roche have completed patient enrollment in the TENAYA and LUCERNE phase 3 clinical trials investigating faricimab for the treatment of wet age-related macular degeneration (AMD). The phase 3 YOSEMITE and RHINE diabetic macular edema (DME) clinical trials completed patient enrollment
- Tom Frinzi to Retire; Warren Foust Appointed President of J&J Vision Surgicalhttps://modernod.com/news/tom-frinzi-to-retire-from-johnson-replaced-by-warren-foust/2477156/Johnson & Johnson Vision announced that Warren Foust will assume the role of Worldwide President, Surgical for Johnson & Johnson Vision, effective December 2. Mr. Foust replaces Tom Frinzi, who will retire at the end of 2019 after a 35-year career in ophthalmology. Mr. Frinzi was
- AAO and ASCRS Launch “Ophthovation” Joint Venture Business Innovation Conferenceshttps://modernod.com/news/aao-and-ascrs-launch-ophthovation-joint-venture-business-innovation-conferences/2477151/Two of the world’s largest ophthalmic organizations have finalized their joint venture “Ophthovation” to develop business conferences that accelerate innovation in ophthalmology. Called the Ophthovation Conference, the meeting will be held every year prior to the annual meetings of th